FindMyKOL
Clinical trialNCT03371108CompletedPhase 3Interventional

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

NCT03371108 is a phase 3 interventional trial sponsored by Gan and Lee Pharmaceuticals, USA. As of 21 Nov 2026, it is completed. It studies Gan & Lee Insulin Glargine Injection and Lantus® in Diabetes Mellitus, Type 2. The registry lists an enrollment of 567 participants at 57 sites in 1 country. The registry lists a start date of 31 Oct 2017 and a primary completion date of 17 Apr 2019.

SponsorGan and Lee Pharmaceuticals, USAEnrollment567Diabetes Mellitus, Type 2
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03371108
FieldValue
Registry IDNCT03371108
StatusCompleted
PhasePhase 3
Study typeInterventional trial
Lead sponsorGan and Lee Pharmaceuticals, USA
Enrollment567
Registered sites57
Countries1
ConditionsDiabetes Mellitus, Type 2
DrugsGan & Lee Insulin Glargine Injection and Lantus®
Start31 Oct 2017
Primary completion17 Apr 2019
Study completion17 Apr 2019
Last update posted1 Apr 2022

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Primary Objective: • To evaluate equivalence of Gan \& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity Secondary Objective: Immunogenicity: • To evaluate the percentage of subjects with negative anti-insulin antibodies (AIA) at baseline who develop confirmed positive AIA up to Week 26, the percentage of subjects with at least a 4-fold increase in titers compared to baseline value, mean change from baseline in AIA titers between treatment groups, the percentage of subjects with confirmed positive AIA who develop any anti-insulin neutralizing antibodies up to visit Week 26, and the percentage of subjects in each treatment group with confirmed positive AIA up to visit Week 26 Safety: • To evaluate the safety of Gan \& Lee Insulin Glargine Injection in comparison with that of Lantus® Efficacy: • To evaluate the efficacy of Gan \& Lee Insulin Glargine Injection in comparison with that of Lantus®

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

57 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Alabama, United States3 sites
  • Simon Williamson Clinic

    Birmingham

  • University of Alabama at Birmingham

    Birmingham

  • Terence T. Hart, Md

    Tuscumbia

Arizona, United States1 site
  • Family Practice Specialists

    Phoenix

California, United States4 sites
  • Valley Research

    Fresno

  • the Rose Salter Medical Research Foundation

    Newport Coast

  • California Medical Research Association

    Northridge

  • Northern California Research Corp.

    Sacramento

Connecticut, United States2 sites
  • Cmr of Greater New Haven, Llc

    Hamden

  • Chase Medical Research, Llc

    Waterbury

Florida, United States11 sites
  • Meridien Research

    Bradenton

  • the Center for Diabetes and Endocrine Care

    Fort Lauderdale

  • Homestead Associates in Research

    Homestead

  • Biotech Pharmaceutical Group, Llc

    Miami

  • Genoma Research Group

    Miami

  • Miami Dade Medical Research Institute, Llc

    Miami

  • New Horizon Research Center

    Miami

  • Suncoast Clinical Research, Inc.

    New Port Richey

  • Peninsula Research

    Ormond Beach

  • Oviedo Medical Research

    Oviedo

  • Metabolic Research Institute

    West Palm Beach

Georgia, United States4 sites
  • River Birch Research Alliance, Llc

    Blue Ridge

  • Iresearch Atlanta

    Decatur

  • Sestron Clinical Research

    Marietta

  • Endocrine Research Solutions, Inc.

    Roswell

Hawaii, United States1 site
  • East-West Medical Research Institute

    Honolulu

Illinois, United States3 sites
  • Cedar Crosse Research Center

    Chicago

  • John H. Stroger Jr. Hospital of Cook County

    Chicago

  • Midwest Crc

    Crystal Lake

Iowa, United States1 site
  • Iowa Diabetes and Endocrinology Research Center

    West Des Moines

Kentucky, United States2 sites
  • Kentucky Diabetes Endocrinology Center

    Lexington

  • L-Marc Research Center

    Louisville

Massachusetts, United States1 site
  • Activmed Practices and Research - Methuen

    Methuen

Nevada, United States1 site
  • Palm Research Center, Inc.

    Las Vegas

North Carolina, United States1 site
  • Physicians East, Pa

    Greenville

North Dakota, United States1 site
  • Lillestol Research Llc

    Fargo

Ohio, United States3 sites
  • Aventiv Research, Inc.

    Columbus

  • Endocrinology Associates, Inc.

    Columbus

  • Primed Clinical Research

    Dayton

South Carolina, United States1 site
  • Mountain View Clinical Research

    Greer

Tennessee, United States3 sites
  • Clinsearch - Clinical Research Specialists

    Chattanooga

  • University Diabetes & Endocrine Consultants

    Chattanooga

  • New Phase Research & Development

    Knoxville

Texas, United States7 sites
  • Austin Regional Clinic

    Austin

  • Texas Diabetes & Endocrinology - Central Austin

    Austin

  • Texas Diabetes & Endocrinology - South Austin

    Austin

  • Sante Clinical Research

    Kerrville

  • Texas Diabetes & Endocrinology - Round Rock

    Round Rock

  • Clinical Trials of Texas

    San Antonio

  • Northeast Clinical Research of San Antonio

    Schertz

Utah, United States3 sites
  • Radiant Research

    Murray

  • Wasatch Clinical Research, Llc

    Salt Lake City

  • Advanced Clinical Research

    West Jordan

Virginia, United States1 site
  • Burke Internal Medicine & Research

    Burke

Washington, United States2 sites
  • Stonesifer Clinical Research

    Federal Way

  • Rainier Clinical Research Center, Inc.

    Renton

Wisconsin, United States1 site
  • Clinical Investigations Specialists-Wisconsin

    Kenosha

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashington: 2 sitesWA2MontanaMTNorth Dakota: 1 siteND1MinnesotaMNWisconsin: 1 siteWI1MichiganMINew YorkNYMassachusetts: 1 siteMA1Rhode IslandRIOregonORIdahoIDSouth DakotaSDIowa: 1 siteIA1Illinois: 3 sitesIL3IndianaINOhio: 3 sitesOH3PennsylvaniaPANew JerseyNJConnecticut: 2 sitesCT2California: 4 sitesCA4Nevada: 1 siteNV1WyomingWYNebraskaNEMissouriMOKentucky: 2 sitesKY2West VirginiaWVVirginia: 1 siteVA1MarylandMDDelawareDEArizona: 1 siteAZ1Utah: 3 sitesUT3ColoradoCOKansasKSArkansasARTennessee: 3 sitesTN3North Carolina: 1 siteNC1South Carolina: 1 siteSC1New MexicoNMOklahomaOKLouisianaLAMississippiMSAlabama: 3 sitesAL3Georgia: 4 sitesGA4Hawaii: 1 siteHI1Texas: 7 sitesTX7Florida: 11 sitesFL11District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Gan & Lee Insulin Glargine InjectionLantus®
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03371108

Each answer restates registry values shown on this page.

What is NCT03371108?

NCT03371108 is a phase 3 interventional trial sponsored by Gan and Lee Pharmaceuticals, USA. It studies Gan & Lee Insulin Glargine Injection and Lantus® in Diabetes Mellitus, Type 2.

Who leads NCT03371108?

The registry names Elena A. Christofides, MD, FACE (principal investigator, Endocrinology Research Associates, Inc.) and Jia Lu, PhD (study director, Gan & Lee Pharmaceuticals, USA) as overall officials.

Where does NCT03371108 run?

The registry lists 57 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT03371108 study?

The registered drug and biological interventions are Gan & Lee Insulin Glargine Injection and Lantus®.

When did NCT03371108 end?

The registry lists a primary completion date of 17 Apr 2019 and a study completion date of 17 Apr 2019. The sponsor last updated the record on 1 Apr 2022.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.